Outcomes of Sacral Neuromodulation and Intradetrusor Onabotulinum Toxin in the Management of Stroke Associated Urinary Incontinence
Open Access
- 31 March 2025
- journal article
- research article
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 29 (1) , 10-16
Abstract
Purpose: Urgency urinary incontinence (UUI) is a common finding in patients with a history of stroke or cerebrovascular accident (CVA). UUI is associated with impaired quality of life as well as increased morbidity, mortality, and need for institutionalization. Medical therapy is often limited by side effects and/or cost prohibitiveness. As a result, third-line therapy is often implemented. The objective is to determine the efficacy of sacral neuromodulation (SNM) and onabotulinum toxin (BTX) in the management of post-CVA UUI.Methods: Retrospective analysis was performed to identify patients with post-CVA UUI who underwent SNM or BTX at a large academic medical center. The primary outcome was patient symptom response to third-line therapy. Treatment response was determined using the global response assessment scale. Patients reporting >50% improvement were categorized as having significant response. Secondary endpoints were proportion of patients achieving total dry and duration of therapy for those achieving significant response.Results: One hundred seventy-seven patients were identified (95 BTX, 82 SNM). Patients in the BTX group were older (71.9 years vs. 67.4 years, P=0.02) with otherwise similar demographics. Rate of symptom improvement to >50% of baseline was similar between the groups (66% of BTX, 61% of SNM, P=0.46) as was rate of patients experiencing total dryness (24% of BTX, 16% of SNM, P=0.17). Among patients achieving significant improvement there was no difference in continuation of therapy between the BTX and SNM groups. Younger age was identified as a predictor of >50% symptom improvement (odds ratio, 0.96; P=0.04) and treatment discontinuation (hazard ratio, 0.97; P=0.04) in SNM. Most common adverse events were urinary tract infection in BTX (11%) and pain in SNM (4%).Conclusions: BTX and SNM show roughly equal efficacy in the management of post-CVA UUI with nearly two-thirds of patients achieving significant benefit.Keywords
This publication has 22 references indexed in Scilit:
- Inequities in Filled Overactive Bladder Medication Prescriptions in the USJAMA Network Open, 2023
- SUFU white paper on overactive bladder anticholinergic medications and dementia riskNeurourology and Urodynamics, 2022
- Systematic Literature Review and Meta-Analysis of Sacral Neuromodulation (SNM) in Patients with Neurogenic Lower Urinary Tract Dysfunction (nLUTD): Over 20 Years’ Experience and Future DirectionsAdvances in Therapy, 2021
- Interventions for treating urinary incontinence after stroke in adultsCochrane Database of Systematic Reviews, 2019
- Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized TrialEuropean Urology, 2018
- Impact of Age and Comorbidities on Use of Sacral NeuromodulationJournal of Urology, 2017
- Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of TreatmentJournal of Urology, 2016
- Urinary incontinence after ischemic stroke: Clinical and urodynamic studiesNeurourology and Urodynamics, 2013
- The relationship between subjective and objective assessments of sacral neuromodulation effectiveness in patients with urgency-frequencyNeurourology and Urodynamics, 2008
- Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesionsUrology, 2006